Linda McCart

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers”.

Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers

Cell Reports Medicine(2025)10.1016/j.xcrm.2025.102154

N/A

0.212DataRank · unranked

3 citations

Aranzazu Fernandez-Martinez, Tanmayi D. Vashist, Matthew V. Holt, LaTerrica Williams, Jonathan T. Lei +26 more

Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4562

N/A

0DataRank · unranked

1 citations

Woonyoung Choi, Susan Halabi, Bin Luo, Hikmat Al‐Ahmadie, Jonathan E. Rosenberg +12 more

Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4521

N/A

0DataRank · unranked

0 citations

Susan Halabi, Bin Luo, Jonathan E. Rosenberg, Woonyoung Choi, Hikmat Al‐Ahmadie +12 more